Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00299494
Status:
COMPLETED
Last Update Posted:
2018-03-08
First Post:
2006-03-02
Brief Title:
Study Evaluating Inotuzumab Ozogamicin CMC-544 Administered In Combination With Rituximab In Subjects With Non-Hodgkins Lymphoma NHL
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 12 Study Of Cmc-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-cell Non-hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2018-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine the tolerability the initial safety profile and maximum tolerated dose and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin CMC-544 in combination with rituximab in subjects with follicular diffuse large B-Cell or mantle cell NHL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-005436-27 | EUDRACT_NUMBER | Alias Study Number | None |
| B1931004 | OTHER | None | None |